



AKIGAI



Christian Kersten, MD PhD
Oncologist, Researcher
Founder, CEO




Marte Cameron, MD PhD
Oncologist, Researcher
Founder, CMO

Our Mission:

To bring an EGFR-inhibitor to as many neuropathic pain patients as possible, as soon as possible

- Clinical serendipity (2007)
- POC >100 patients
- Broad use patent
- Academic spin-out
- Established 2023
- Oslo, Norway
- Micro SME (1.5 full-time employees)
- Pre-revenue stage
- 2 products in development
- Orphan Drug Designation; Phase 3 ready



	Date	Meeting type
Academic Researchers	05 / 2018	SME Office Briefing Meeting #1
	09 / 2018	Presubmission meeting ODD
	01 / 2020	SME Office Briefing Meeting #2
AKIGAI	11 / 2023	SME Office Briefing Meeting #3
	12 / 2023	SME Office Briefing Meeting #4
	01 / 2024	Presubmission meeting ODD
	Orphan Drug Designation (06.2024)	
		SME Office informal contact
	11 / 2024	Presubmission Meeting SA/PA
		SME Office informal contact
	12 / 2024	Presubmission Meeting PRIME

Offices represented at SME meetings

- ✓ SME
- ✓ Scientific Advice
- ✓ PRIME
- ✓ Orphan Medicines
- ✓ Clinical Pharm.
- ✓ Regulatory Affairs
- ✓ Pediatric Medicines
- ✓ Quality
- ✓ CNS
- ✓ Academia
- ✓ National expert

- SME status has been instrumental in developing a viable strategy that effectively fulfills our mission
- EMA validation gave us the confidence to move forward and was crucial in securing funding.

